A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Eisai learns from Biogen’s Aduhelm disaster
Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Your 2023 wildcard predictions revealed
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
Go or no go? Lecanemab’s destiny approaches
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
CTAD 2022 – Lexeo takes baby steps towards Alzheimer’s gene therapy
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
